Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Takeda highlights new proton pump inhibitor as “novel treatment option”

Takeda highlights new proton pump inhibitor as “novel treatment option”

11th January 2008

Takeda has stated its hopes to see its new proton pump inhibitor TAK-390MR contribute as a “novel treatment option” for patients with acid-related disorders.

TAK-390MR is a proton pump inhibitor that employs a novel modified release technology on dexlansoprazole, which was discovered by Takeda.

The drug candidate’s development has been taken on by TAP Pharmaceutical Products, a joint venture with Abbot Laboratories.

A series of clinical trials have investigated the efficacy and safety profile of TAK-390MR with global studies taking place across more than 20 countries, evaluating more than 6,000 subjects with erosive and non-erosive gastroesophageal reflux disease.

These studies have now supported a New Drug Application to the US Food and Drug Administration this week, for its use in the treatment and maintenance of patients with erosive esophagitis and non-erosive reflux disease.

Yasuchika Hasegawa, president of Takeda, indicated that the company expected TAK-390MR to “enhance TAP’s well established gastroenterology franchise” as well as meet the unmet medical needs of patients.

Also this week, Takeda has stated it hopes to see its developmental drug candidate alogliptin (SYR-3222) become an “important treatment option” to patients with type two diabetes.

We currently have 7 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.